GSK plans five Phase 3 studies for gynecological cancer ADC from Hansohnews2026-04-12T14:10:11+00:00April 12th, 2026|Endpoints News|
China biotech’s CRISPR therapy suggests US drugmakers will face competitionnews2026-04-10T15:54:15+00:00April 10th, 2026|Endpoints News|
Gilead takes another big swing at expanding beyond HIVnews2026-04-08T15:10:43+00:00April 8th, 2026|Endpoints News|
Insmed shelves Brinsupri in skin disease after mid-stage flopnews2026-04-08T10:06:51+00:00April 8th, 2026|Endpoints News|
ARPA-H selects three teams in $100M effort to repair and regrow ailing jointsnews2026-04-07T15:41:41+00:00April 7th, 2026|Endpoints News|
Sanofi bispecific sails through asthma, sinusitis trials, but disappoints in eczemanews2026-04-07T10:44:28+00:00April 7th, 2026|Endpoints News|
Amgen seeks to buoy Tepezza with injectable data in face of incoming competitionnews2026-04-06T15:37:41+00:00April 6th, 2026|Endpoints News|
Takeda ends partnership with Denali amid restructuringnews2026-04-06T14:19:14+00:00April 6th, 2026|Endpoints News|
Novo and Lilly battle over GLP-1 claims only a head-to-head trial can answernews2026-04-02T15:31:07+00:00April 2nd, 2026|Endpoints News|
Alto Neuroscience shelves schizophrenia cognitive impairment program after Phase 2 missnews2026-04-02T11:02:01+00:00April 2nd, 2026|Endpoints News|
